Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;32(10):1505-9.
doi: 10.1016/j.leukres.2008.03.002. Epub 2008 Apr 10.

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

Masamitsu Yanada  1 , Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Hagop Kantarjian, Elihu Estey
Affiliations

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

Masamitsu Yanada et al. Leuk Res. 2008 Oct.

Abstract

Prognostic relevance of blood counts at complete remission (CR) in acute myeloid leukemia (AML) is not clear. To address this issue, we analyzed 891 AML patients in first CR. From the data of randomly selected 446 patients (training set), we first established optimal cutoffs for neutrophil and platelet counts and hemoglobin level at CR in terms of relapse-free survival (RFS). Patients whose counts were higher than each optimal cutoff were shown to have significantly better RFS (p<0.01 for neutrophil and platelets, and p=0.02 for hemoglobin). Then we tested whether these cutoffs were, after accounting for better known prognostic covariates, also predictive of RFS in the remaining 445 patients (validation set). Our data revealed that higher neutrophil count was independently predictive of longer RFS in the validation set (hazard ratio 1.38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relapse-free survival according to neutrophil count at time of complete remission in the second group. The cutoff established in the first group (75th percentile, 8.2 × 109/L) were applied.
Fig. 2
Fig. 2
Relapse-free survival according to platelet count at time of complete remission in the second group. The cutoff established in the first group (75th percentile, 320 × 109/L) were applied.
Fig. 3
Fig. 3
Relapse-free survival according to hemoglobin level at time of complete remission in the second group. The cutoff established in the first group (25th percentile, 9.5 g/dL) were applied.
See this image and copyright information in PMC

References

    1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154–63. - PubMed
    1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–907. - PubMed
    1. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, et al. Factors related to length of complete remission in adult acute leukemia. Cancer. 1980;45:2017–29. - PubMed
    1. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69–79. - PubMed
    1. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64–70. - PubMed

Substances